Liminatus Pharma, Inc.
LIMN · XNASCIK 1971387fmd_1NECYSA6YKVYRHSH4YZAXTDTZ9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2024 to Jun 30, 2026, 10 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | 3 | – |
| Total operating expenses | 3 | 3 |
| Operating income | (3) | (3) |
| Interest expense | 0 | 0 |
| Interest and investment income | 0 | 0 |
| Other non-operating income (expense) | (0) | (7) |
| Net income | (4) | (10) |